RecruitingPHASE2, PHASE3NCT06333041
Study of Cannabidiol in Sanfilippo Syndrome
Studying Sanfilippo Syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Intervention
- Epidiolex(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06333041 on ClinicalTrials.govOther trials for Sanfilippo Syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06614894An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS IIIOzlem Goker-Alpan
- RECRUITINGPHASE2, PHASE3NCT02716246Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHUltragenyx Pharmaceutical Inc